1. FRI0161 A Phase 1B/2A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XMAB®5871 in Patients with Rheumatoid Arthritis. (9th June 2015) Authors: Jaraczewska-Baumann, M.; Korkosz, M.; Sulyok, G.; Sramek, P.; Rojkovich, B.; Daniluk, S.; Bartalos, J.; Zack, D.J.; Foster, P. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA. (23rd January 2014) Authors: Holz, J.-B.; Sargentini-Maier, L.; De Bruyn, S.; Gachályi, B.; Udvaros, I.; Rojkovich, B.; Bruk, S.; Sramek, P.; Korkosz, M.; Krause, K.; Schoen, P.; D'Artois, J.; Verschueren, K.; Willems, W.; De Swert, K.; Arold, G. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗